Breaking News: Basilea Strikes Deal with Innoviva for US Release of Life-Saving Antibiotic Zevtera
Description:
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US).
The Impact on You:
With the US release of the life-saving antibiotic Zevtera, patients suffering from severe bacterial infections, including MRSA, will have access to an effective treatment option. This could potentially improve outcomes for individuals facing such serious health challenges.
The Global Impact:
The partnership between Basilea and Innoviva for the distribution of Zevtera in the US has the potential to benefit patients worldwide. This could lead to greater availability of the antibiotic in other countries, ultimately saving more lives and combating the spread of antibiotic-resistant bacteria on a global scale.
Conclusion:
This collaboration between Basilea and Innoviva marks a significant advancement in the fight against severe bacterial infections, particularly MRSA. The US release of Zevtera signifies a step forward in providing patients with access to life-saving treatments, while also contributing to the global effort to address antibiotic resistance.
